Evidence map›Paper›PMID 35611667›Full record

Trial reportGut and liver2023

Efficacy of a Synbiotic Containing

Joo Hyun Oh, Yeon Sil Jang, Danbee Kang, Hong Seog Kim, Eui-Joong Kim, So-Young Park, Cheol-Hyun Kim, Yang Won Min, Dong Kyung Chang

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Gut and liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Management of irritable bowel syndrome: a narrative review.Translational gastroenterology and hepatology · 2024
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Joo Hyun OhDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0002-9140-9498
Yeon Sil JangDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0003-1737-5426
Danbee KangDepartment of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0003-0244-7714
Hong Seog KimYoudam Co., Ltd., Cheonan, Korea.ORCID 0000-0002-6546-3976
Eui-Joong KimGenofocus, Inc., Daejeon, Korea.ORCID 0000-0001-5814-5112
So-Young ParkLaboratory of Pharmacognosy, College of Pharmacy, Dankook University, Cheonan, Korea.ORCID 0000-0002-1065-6746
Cheol-Hyun KimDepartment of Animal Resources Science, College of Biotechnology and Bioengineering, Dankook University, Cheonan, Korea.ORCID 0000-0002-1905-9948
Yang Won MinDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-7471-1305
Dong Kyung ChangDepartment of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID 0000-0001-8925-4629
Samsung Medical Center · KRDankook University · KREulji University · KRSamsung (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: There is increasing evidence that supplementation with pre- and probiotics appears to have positive effects on irritable bowel syndrome (IBS). The aim of this study was to determine the effects of a new synbiotic formulation on gastrointestinal symptoms in elderly patients with IBS. Methods: Sixty-seven IBS patients aged ≥60 years were randomly assigned to either a placebo group (n=34) or a synbiotic group (n=33). During a 4-week intervention, subjects used a placebo or a synbiotic containing Results: Overall, responder rates were significantly higher in the synbiotic group (51.5%) than in the placebo group (23.5%) (p=0.017). Abdominal pain (58.8% vs 81.8%) and psychological well-being (26.4% vs 60.6%) were noticeably improved in the synbiotic group (p=0.038 and p=0.004, respectively). However, there were no significant differences in gas and bloating symptoms (p=0.88 and p=0.88, respectively). In patients with constipation-dominant and diarrhea-dominant IBS (n=16), the synbiotic significantly improved abdominal pain and defecation symptoms (responder rates for the placebo vs the synbiotic: 22.2% vs 85.7%, p=0.04). There were no adverse events in either group. Conclusions: The results indicate that this new synbiotic supplement can potentially relieve abdominal symptoms in elderly IBS patients.

Indexed as

Irritable Bowel SyndromeLacticaseibacillus paracaseiOpuntiaSynbioticsAbdominal PainAgedDouble-Blind MethodHumansTreatment OutcomeAgedIrritable bowel syndromeSynbiotics

Identifiers

PMID35611667
PMCPMC9840930
OpenAlexW4281484708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.